Annals of Pharmacotherapy最新文献

{"title":"Response to \"Evaluation of Symptom-Triggered Benzodiazepines Versus Phenobarbital for Alcohol Withdrawal Syndrome in Trauma-Surgical Intensive Care Patients\".","authors":"Mark K Su, Heather Brunette","doi":"10.1177/10600280261444366","DOIUrl":"10.1177/10600280261444366","url":null,"abstract":"","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1131"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Oxycodone Combined With Thoracic Paravertebral Nerve Block for Postoperative Analgesia in Esophageal Cancer Surgery: A Retrospective Study.","authors":"Weiwei Li, Fujun Wang, Hangwei Zhou, Zhiyuan Huai, Yue Fang, Dongshui Liu, Huijian Shi, Wensheng Zhang","doi":"10.1177/10600280251349200","DOIUrl":"10.1177/10600280251349200","url":null,"abstract":"<p><strong>Background: </strong>Thoracoscopic esophagectomy for esophageal cancer often results in substantial postoperative pain, which may impair recovery and increase the risk of complications. Effective and well-tolerated analgesia is essential to improve clinical outcomes.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of combining thoracic paravertebral nerve block (TPVB) with oxycodone-based intravenous patient-controlled analgesia (IV PCA) for postoperative pain management in patients undergoing thoracoscopic esophagectomy.</p><p><strong>Methods: </strong>A retrospective study was conducted from April 2022 to April 2023, including 160 patients undergoing thoracoscopic esophagectomy. Patients were divided into 4 groups: oxycodone IV PCA with TPVB (OT group), sufentanil IV PCA with TPVB (ST group), oxycodone IV PCA alone (O group), and sufentanil IV PCA alone (S group). Pain scores, opioid consumption, sedation levels, time to first mobilization, serum inflammatory markers (TNF-α, IL-6, IL-10), adverse events, and patient satisfaction were assessed and compared across groups.</p><p><strong>Results: </strong>OT group showed significantly lower pain scores at 12, 24, and 48 hours postoperatively (<i>P</i> < .01), along with reduced opioid consumption and fewer PCA attempts. Patients in the OT group mobilized earlier and reported higher satisfaction compared with the O and S groups. Inflammatory markers TNF-α and IL-6 were significantly lower, and IL-10 was higher in the OT group at 24 and 48 hours postoperatively, indicating a more favorable anti-inflammatory profile.</p><p><strong>Conclusion and relevance: </strong>This study demonstrates that combining TPVB with oxycodone IV PCA provides superior analgesia, faster recovery, and better anti-inflammatory effects than sufentanil-based or single-modality regimens, with a low incidence of adverse events.These findings highlight a clinically effective multimodal strategy for postoperative pain control in esophageal cancer surgery. Based on the data, this approach may reduce chronic pain and improve recovery quality, supporting its broader clinical application.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1066-1074"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sulopenem Etzadroxil/Probenecid: A Comprehensive Review of an Oral Thiopenem.","authors":"Brandon K Hawkins, Helen Ding, Zaynab Amin","doi":"10.1177/10600280261444403","DOIUrl":"10.1177/10600280261444403","url":null,"abstract":"<p><strong>Objective: </strong>To review the pharmacology, pharmacokinetics/pharmacodynamics, development, spectrum of activity, clinical trials, dosing/administration, and role of sulopenem etzadroxil/probenecid in current practice.</p><p><strong>Data sources: </strong>PubMed, EMBASE, and ClinicalTrials.gov were queried using the terms Sulopenem, CP-70429, and CP-65207.</p><p><strong>Study selection and data extraction: </strong>Articles written in English and published from January 1, 1989 to March 1, 2026 relating to development, clinical pharmacology, antimicrobial activity/testing, safety, and clinical trial data of sulopenem were reviewed.</p><p><strong>Data synthesis: </strong>An oral penem prodrug coformulated with probenecid to increase exposure, sulopenem etzadroxil is active against many Enterobacterales, including extended-spectrum β-lactamase (ESBL) and AmpC producers. Sulopenem did not demonstrate noninferiority in the treatment of complicated urinary tract infections (cUTIs) compared with ertapenem followed by susceptibility-guided oral therapy, or complicated intraabdominal infections compared with ertapenem followed by either amoxicillin/clavulanate or ciprofloxacin and metronidazole. Compared with ciprofloxacin in the treatment of uncomplicated UTI (uUTI), sulopenem etzadroxil/probenecid did not demonstrate noninferiority in patients with ciprofloxacin-susceptible isolates. However, higher composite response rates were observed in infections caused by ciprofloxacin-nonsusceptible isolates. Sulopenem etzadroxil/probenecid demonstrated noninferiority compared with amoxicillin/clavulanate for the treatment of uUTI.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Sulopenem etzadroxil/probenecid is active against commonly isolated uropathogens that may be difficult to treat with traditional oral antibiotics, such as ESBL and AmpC producers. Agents such as gepotidacin and pivmecillinam may provide similar treatment options for uUTI, though these have not been directly compared with sulopenem etzadroxil/probenecid.</p><p><strong>Conclusions: </strong>Sulopenem etzadroxil/probenecid provides an additional oral treatment option for uUTI in adult women with limited or no alternative options.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1118-1129"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Rahul Bisht, Arusha Desai, Esteban Marcelo Mogrovejo Carrión, Anjali Bhardwaj, Sidharth Misra, Tejesh Bangalore Shivashankar, Ramita Gupta","doi":"10.1177/10600280261437728","DOIUrl":"10.1177/10600280261437728","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of mepolizumab, a humanized monoclonal antibody that targets interleukin-5, a key mediator in eosinophilic inflammation, in reducing moderate-to-severe exacerbations among patients with eosinophilic chronic obstructive pulmonary disease (COPD).</p><p><strong>Data sources: </strong>PubMed, Scopus, Web of Science, and Cochrane databases were systematically searched using the terms: \"Mepolizumab,\" \"COPD,\" \"Chronic Obstructive Pulmonary Disease,\" for randomized controlled trials comparing subcutaneous mepolizumab (100 mg every 4 weeks) with placebo in patients with eosinophilic COPD from inception till July 2025.</p><p><strong>Study selection and data extraction: </strong>Randomized controlled trials comparing subcutaneous mepolizumab with placebo in adults with eosinophilic COPD were included. Two independent reviewers screened studies and extracted data. Finally, 4 studies with a total of 1953 patients were included. Of these, 978 (50.0%) received mepolizumab.</p><p><strong>Data synthesis: </strong>Statistical analysis was performed using R software (version 4.5.0). Mepolizumab significantly prolonged the time to first moderate or severe exacerbation (hazard ratio [HR] = 0.80; 95% confidence interval [CI] 0.69-0.92; <i>P</i> = 0.016) and reduced the rate of moderate-to-severe exacerbations (rate ratio 0.80; 95% CI 0.78-0.83; <i>P</i> < 0.001). The risk of adverse events (AEs) (risk ratio [RR] = 1.00; 95% CI 0.95-1.06; <i>P</i> = 0.962) was similar between groups, while the risk of serious adverse events or death (RR = 0.83; 95% CI 0.72-0.96; <i>P</i> = 0.031) was significantly lower in the mepolizumab group.Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:Mepolizumab provides a targeted, biomarker-guided treatment option, potentially reducing exacerbations without the added safety concerns like infections and metabolic complications as seen with existing therapies.</p><p><strong>Conclusion and relevance: </strong>Mepolizumab reduces the time to first moderate or severe exacerbation and prolongs symptom-free periods in patients with eosinophilic COPD, without increasing the risk of AEs.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1090-1102"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Area Under the Curve vs Trough-Based Vancomycin Monitoring in Pediatric Patients.","authors":"Meagan A Wallace, Mary Kathryn Vance, Caleb McMinn, Brent Curry, Amanda L Elchynski","doi":"10.1177/10600280261493966","DOIUrl":"https://doi.org/10.1177/10600280261493966","url":null,"abstract":"<p><strong>Background: </strong>Trough-based monitoring was previously the primary way to monitor vancomycin; however, 2020 vancomycin consensus guidelines recommend area under the curve (AUC)-based monitoring as the preferred strategy. Data regarding this approach remain limited in the pediatric population.</p><p><strong>Objective: </strong>To compare the proportion of pediatric patients achieving therapeutic vancomycin serum concentrations using AUC vs trough-based monitoring and evaluate the safety and efficacy of both strategies.</p><p><strong>Methods: </strong>This is a single-center retrospective cohort study comparing trough- and Bayesian AUC-based vancomycin monitoring. Patients aged 28 days to 18 years on vancomycin with at least 2 appropriately obtained levels were included. Patients were excluded for suspected or confirmed central nervous system infection, renal dysfunction at vancomycin initiation, neonate or postmenstrual age <44 weeks, or use of continuous vancomycin. The primary outcome was the proportion of patients achieving therapeutic vancomycin serum concentrations. Secondary outcomes included proportion of patients achieving therapeutic goal by the second pharmacokinetic evaluation, time to therapeutic goal, 30- and 90-day all-cause mortality, number of dose adjustments, number of serum concentrations collected, proportion of appropriately timed serum concentrations, and incidence of acute kidney injury (AKI).</p><p><strong>Results: </strong>Eighty-six patients were included: 49 AUC and 37 trough. Overall target attainment was higher in the AUC group (95.9% vs 51.4%; <i>P</i> < .001). The AUC group had a lower final vancomycin dose (<i>P</i> < .001), fewer dose adjustments (<i>P</i> = .004), serum concentrations obtained (<i>P</i> = .02), and more appropriately timed serum concentrations (<i>P</i> = .02). Incidence of AKI and 30- and 90-day all-cause mortality did not differ between groups.</p><p><strong>Conclusion and relevance: </strong>Area under the curve monitoring was associated with higher therapeutic goal attainment, lower final vancomycin doses, higher percentage of appropriately timed serum concentrations, fewer serum concentrations drawn, and fewer dosage adjustments. These findings add pediatric-specific evidence supporting 2020 guideline recommendations and indicate Bayesian area under the curve monitoring is a feasible, resource-efficient strategy in this population.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261493966"},"PeriodicalIF":2.5,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults.","authors":"Lauren Lewis, Jackie Liu, Anu Sharma, Lihui Yuan","doi":"10.1177/10600280261494605","DOIUrl":"https://doi.org/10.1177/10600280261494605","url":null,"abstract":"<p><strong>Objective: </strong>To review the pharmacology, efficacy, and safety of palopegteriparatide for the treatment of chronic hypoparathyroidism in adults.</p><p><strong>Data sources: </strong>A literature search was conducted in PubMed from September 2015 to August 2026. All relevant publications, package inserts, and clinical trials with palopegteriparatide were reviewed. Keywords used were: palopegteriparatide, hypoparathyroidism, parathyroid hormone (PTH), TransCon PTH, hypocalcemia, PTH(1-34), clinical trials and quality of life.</p><p><strong>Data extraction: </strong>All relevant publications, abstracts, package inserts, and clinical trials involving palopegteriparatide were reviewed.</p><p><strong>Data synthesis: </strong>Palopegteriparatide is a once-daily subcutaneous injection that uses TransCon technology to treat chronic hypoparathyroidism in adults. Palopegteriparatide led to 93% of participants achieving complete independence from conventional therapy (calcium and active vitamin D) in phase 3 trials. Pill burden decreased from 6.7 at baseline to 0.26 at week 52, and the health-related quality of life of participants significantly increased. The mild-to-moderate adverse effects of palopegteriparatide support its overall favorable tolerability profile.Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Palopegteriparatide is a new PTH analog that mimics physiologic PTH exposure, resulting in more stable serum calcium levels and improved renal handling of calcium and phosphate.</p><p><strong>Conclusion: </strong>Palopegteriparatide is the only Food and Drug Administration-approved medication available that addresses PTH deficiency in chronic hypoparathyroidism. It provides a 24-hour continuous release of PTH enabling effective management of PTH insufficiency.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261494605"},"PeriodicalIF":2.5,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meropenem Exposure, Target Attainment, and Therapeutic Drug Monitoring Practices in Critically Ill Adults Receiving Continuous Renal Replacement Therapy: A Systematic Review.","authors":"Nazatul Adhwa Mohd Rozi, Lim Jia Hui, Shamin Saffian, Mohd Makmor-Bakry, Aliza Mohamad Yusof, Ruslinda Mustafar, Muhammad Nordin M Saud, Nor Asyikin Mohd Tahir","doi":"10.1177/10600280261489958","DOIUrl":"https://doi.org/10.1177/10600280261489958","url":null,"abstract":"<p><strong>Objective: </strong>To critically evaluate meropenem pharmacokinetics/pharmacodynamics (PK/PD) target attainment, therapeutic drug monitoring (TDM), infusion strategies, and clinical outcomes during continuous renal replacement therapy (CRRT).</p><p><strong>Data sources: </strong>Ovid MEDLINE, PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to August 15, 2026, using meropenem, TDM, β-lactam, and CRRT terms, with adult, human, and English-language limits.</p><p><strong>Study selection and data extraction: </strong>Thirteen reports representing 12 unique studies (2 randomized, 10 non-randomized) reporting meropenem concentration data during CRRT were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using RoB 2 or ROBINS-I.</p><p><strong>Data synthesis: </strong>Total clearance ranged from 3.60 to 6.6 L/h. Lower or primary PK/PD target non-attainment ranged from 0% to 26.7%, while aggressive-target non-attainment ranged from 0% to 53.3% in most analyses and reached 93% in 1 study when a minimum inhibitory concentration (MIC) of 8 mg/L was assumed. Continuous or prolonged infusion may facilitate sustained exposure, but comparative evidence was limited. Four used routine TDM; only 2 implemented protocolized TDM-guided dose adjustment. Low exposure was associated with higher mortality in 1 adjusted observational analysis, but evidence for clinical outcomes was of very low certainty.</p><p><strong>Relevance to patient care and clinical practice: </strong>Standardized meropenem regimens cannot be assumed to provide consistent exposure during CRRT. Optimized infusion and timely, protocolized TDM may support individualized dosing when multidisciplinary expertise is available.</p><p><strong>Conclusions: </strong>Available evidence supports a shift from standardized empirical dosing toward individualized, measurement-guided meropenem therapy in patients receiving CRRT.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261489958"},"PeriodicalIF":2.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Clinical Outcomes of Selective Versus Nonselective Beta-Blockers Among Patients With Heart Failure With Reduced Ejection Fraction Receiving Sacubitril/Valsartan.","authors":"Leonie Adjeroh, Khalid M Kamal, L Raymond Guo, Sudarshan Balla, Sijin Wen, Kazuhiko Kido","doi":"10.1177/10600280261493520","DOIUrl":"https://doi.org/10.1177/10600280261493520","url":null,"abstract":"<p><strong>Background: </strong>Beta-blockers, selective (metoprolol succinate or bisoprolol) and nonselective (carvedilol), and angiotensin receptor-neprilysin inhibitors (ARNIs) are the first-line guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). Concomitant use of carvedilol and ARNI (sacubitril/valsartan) may result in additive vasodilatory effects, which may increase the risk of hypotension and limit dose titration of sacubitril/valsartan.</p><p><strong>Objective: </strong>This study examines differences in clinical endpoints between selective and nonselective beta-blocker therapy among patients with HFrEF receiving sacubitril/valsartan.</p><p><strong>Methods: </strong>This retrospective cohort study utilized TriNetX Research Collaborative real-world data. Patients receiving sacubitril/valsartan concomitantly with carvedilol were identified as the intervention cohort, while those receiving metoprolol succinate or bisoprolol served as controls. The primary endpoint was a composite of all-cause mortality or all-cause hospitalization during the 3-year follow-up. Propensity score matching (PSM) balanced confounders. Kaplan-Meier analyses were used to estimate event-free survival, and hazard ratios (HRs) were calculated using Cox proportional hazards models for time-to-event outcomes. Sensitivity analyses were conducted to evaluate the robustness of the findings.</p><p><strong>Results: </strong>Overall, 75 230 patients received carvedilol and 21 587 received metoprolol/bisoprolol. After PSM, 20 939 patients were included in each group. Carvedilol was associated with a higher risk of the primary composite endpoint compared with those taking metoprolol or bisoprolol (52.32% vs 46.29%; HR: 1.21; 95% CI, 1.17-1.24; <i>P</i> < .0001). Carvedilol was also linked to increased hospitalization risk (HR: 1.32; 95% CI, 1.28-1.36; <i>P</i> < .0001) but a modest reduction in mortality (HR: 0.92; 95% CI, 0.87-0.97; <i>P</i> = .0011). In addition, carvedilol was associated with higher risks of hypotension, end-stage renal disease, and bradycardia. Sensitivity analysis results were consistent for the primary endpoint.</p><p><strong>Conclusion and relevance: </strong>Our results suggest that carvedilol may be associated with a higher risk of the composite endpoint, health care utilization, and adverse events but lower all-cause mortality compared with metoprolol or bisoprolol in patients with HFrEF taking sacubitril/valsartan.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261493520"},"PeriodicalIF":2.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Tradipitant for Motion Sickness-A GRADE Assessed Systematic Review and Meta-Analysis.","authors":"Taha Ibrahim, Muhammad Burhan, Zain Ul Abideen Shahid, Ahila Ali, Muhammad Usman, Shaheer Bin Shafiq, Huzaifa Ul Haque Ansari, Muhammad Hasnain Azeem, Ahmed Ali, Jawaria Ibrahim, Ibrahim Nagmeldin Hassan","doi":"10.1177/10600280261474866","DOIUrl":"https://doi.org/10.1177/10600280261474866","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of tradipitant, a neurokinin-1 (NK1) receptor antagonist, for preventing motion sickness-induced vomiting.</p><p><strong>Data sources: </strong>PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception through February 2026 without language or date resrictions.</p><p><strong>Study selection and data extraction: </strong>Randomized controlled trials comparing tradipitant (85 or 170 mg) with placebo in adults with motion sickness were included. Two reviewers independently screened studies, extracted data, assessed risk of bias using Cochrane Risk of Bias 2, and evaluated certainty of evidence using Grading of Recommendations Assessment, Development, and Evaluation.</p><p><strong>Data synthesis: </strong>Three randomized controlled trials (N = 808) were included. Tradipitant significantly reduced overall vomiting vs placebo (risk ratio [RR], 0.38; 95% confidence interval [CI], 0.30-0.48; I² = 0%) and improved the composite nausea/vomiting outcome (RR, 0.48; 95% CI, 0.35-0.65). Serious adverse events and somnolence were comparable between groups, although fatigue was more frequent with tradipitant (RR, 2.66; 95% CI, 1.02-6.93).Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:Unlike antihistamines and anticholinergics, which are frequently limited by sedation and anticholinergic adverse effects, tradipitant significantly reduces motion-induced vomiting with minimal sedation and may benefit patients who do not respond to or cannot tolerate conventional therapies.</p><p><strong>Conclusions: </strong>Tradipitant significantly reduces motion sickness-induced vomiting while maintaining a favorable safety profile, supporting its role as an effective treatment option pending further comparative studies.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261474866"},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential Impact of Selective Serotonin Reuptake Inhibitors on Delayed Onset Muscle Soreness: A Prospective Cohort Study.","authors":"Jack Deitch, Michele LaBotz, Wayne Lamarre, Timothy J Michael, Paul Visich","doi":"10.1177/10600280261493982","DOIUrl":"https://doi.org/10.1177/10600280261493982","url":null,"abstract":"<p><strong>Background: </strong>Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for mood disorders. Their association with musculoskeletal side effects raises the question of potential SSRI impact on exercise-induced muscle damage and recovery.</p><p><strong>Objective: </strong>The purpose of this prospective cohort study was to determine if SSRI use influences muscle function following a bout of eccentric exercise designed to induce delayed onset muscle soreness (DOMS).</p><p><strong>Methods: </strong>Subjects between 18 and 30 years of age were recruited in a university setting. This included 1 group taking SSRIs prescribed by their health care provider, and a control group not using SSRIs. Subjects performed a DOMS induction protocol consisting of 300 eccentric knee extensions on an isokinetic dynamometer. Muscle soreness, thigh circumference, quadriceps flexibility, and isometric quadriceps strength were measured at baseline and at 24-, 48-, 72-, and 96-hour post-DOMS protocol. Comparisons were made between SSRI users and control subjects.</p><p><strong>Results: </strong>Thirty-six subjects included 18 SSRI users and 18 controls. The DOMS protocol induced muscle soreness in both groups (<i>P</i> < .001 when compared with baseline). At 72 hours a between-group difference was observed for thigh muscle flexibility (MD = 11.2, SE = 5.0, 95% CI [0.9, 21.4], <i>P</i> = .033, ηp² = .126) but no additional significant between-group differences in soreness, strength, thigh circumference, or flexibility were noted at any timepoint.</p><p><strong>Conclusion and relevance: </strong>In this population, SSRI use had no effect on muscle soreness, circumference, or strength of the quadriceps following eccentric DOMS-inducing exercise. A difference in flexibility between SSRI and control groups at a single time point likely reflects a Type 1 error and is not likely of clinical consequence. These findings suggest SSRIs do not impair short-term recovery from exercise-induced muscle damage in healthy young adults, but potential SSRI impacts on longer-term training adaptations and recovery in athletic populations remain unknown.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"10600280261493982"},"PeriodicalIF":2.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}